4.1. classification. objective tumour classification system combine patients similar clinical outcome. allows discussion prognosis patients, design clinical trials relatively homogeneous populations, comparison clinical pathological data obtained different hospitals across world, development recommendations treatment patient populations. throughout guidelines union international cancer control (uicc) 8th edition (2017), tumour, node, metastasis (tnm) classification staging pca (table 4.1) eau risk group classification used . latter classification based grouping patients similar risk biochemical recurrence (bcr) radical prostatectomy (rp) external beam radiotherapy (ebrt). changes diagnostic pathway, imaging (e.g., mri, prostate-specific membrane antigen [psma] positron emission tomography computed tomography [pet/ct] scan) biopsy (e.g., increasing number systematic biopsy cores, targeted biopsy) may cause stage shift risk classification systems . although 2017 american joint committee cancer (ajcc) staging 8th edition specifically states clinical staging based digital rectal examination (dre) only, explicit comment made uicc. since clinical stage assessed dre only, included eau (d’amico) risk group classification, ct-stage based dre findings imaging. additional staging information based imaging reported separately. non-palpable pca bilateral positive biopsies extra-prostatic extension (epe) mri would therefore categorised ct1c separate report mri findings. table 4.1: clinical tumour node metastasis (tnm) classification pca clinical tumour node metastasis (tnm) classification pcat - primary tumour (stage based digital rectal examination [dre] only)txprimary tumour cannot assessedt0no evidence primary tumourt1clinically inapparent tumour palpablet1atumour incidental histological finding 5% less tissue resectedt1btumour incidental histological finding 5% tissue resectedt1ctumour identified needle biopsy (e.g. elevated prostate-specific antigen [psa])t2tumour palpable confined within prostatet2atumour involves one half one lobe lesst2btumour involves half one lobe, lobest2ctumour involves lobest3tumour extends palpably prostatic capsulet3aextracapsular extension (unilateral bilateral)t3btumour invades seminal vesicle(s)t4tumour fixed invades adjacent structures seminal vesicles: external sphincter, rectum, levator muscles, and/or pelvic walln - regional (pelvic) lymph nodes1nxregional lymph nodes cannot assessedn0no regional lymph node metastasisn1regional lymph node metastasism - distant metastasis2m0no distant metastasism1distant metastasism1a non-regional lymph node(s)m1b bone(s)m1c site(s) 1 metastasis larger 0.2 cm designated pnmi.2 one site metastasis present, advanced category used. (p)m1c advanced category. pathological staging (ptnm) based histopathological tissue assessment largely parallels clinical tnm, except clinical t1 t2 substages. pathological stages pt1a/b/c exist histopathologically confirmed organ-confined pcas rp pathological stage pt2. current uicc longer recognises pt2 substages . note: eanm recently proposed molecular imaging tnm (‘mitnm’) classification, taking account psma pet/ct findings . prognosis mit, min mim substages likely better t, n counterparts due ‘will rogers phenomenon’; extent prognosis shift remains assessed well practical interest impact . reclassification endorsed uicc ajcc.